POZZI, Samantha
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.471
EU - Europa 5.567
AS - Asia 5.397
SA - Sud America 828
AF - Africa 187
Continente sconosciuto - Info sul continente non disponibili 176
OC - Oceania 32
Totale 25.658
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.249
GB - Regno Unito 2.066
SG - Singapore 1.545
CN - Cina 1.395
IT - Italia 1.002
HK - Hong Kong 656
BR - Brasile 599
VN - Vietnam 590
DE - Germania 526
SE - Svezia 452
FI - Finlandia 335
BD - Bangladesh 268
FR - Francia 255
UA - Ucraina 246
RU - Federazione Russa 230
TR - Turchia 169
IN - India 155
KR - Corea 125
CA - Canada 120
ID - Indonesia 94
BG - Bulgaria 87
AR - Argentina 73
IQ - Iraq 61
JP - Giappone 56
MA - Marocco 56
IE - Irlanda 50
NL - Olanda 48
MX - Messico 45
ZA - Sudafrica 42
ES - Italia 39
PH - Filippine 36
PL - Polonia 36
PK - Pakistan 34
EC - Ecuador 33
CO - Colombia 31
AE - Emirati Arabi Uniti 29
BE - Belgio 29
CL - Cile 25
MY - Malesia 25
LT - Lituania 24
AU - Australia 23
CZ - Repubblica Ceca 23
SA - Arabia Saudita 23
PY - Paraguay 19
AT - Austria 18
EG - Egitto 18
UZ - Uzbekistan 17
VE - Venezuela 17
CH - Svizzera 13
CR - Costa Rica 13
IR - Iran 13
DO - Repubblica Dominicana 12
NO - Norvegia 12
TN - Tunisia 12
JO - Giordania 11
PE - Perù 11
PT - Portogallo 11
UY - Uruguay 11
IL - Israele 10
KE - Kenya 10
TW - Taiwan 10
AZ - Azerbaigian 9
HU - Ungheria 9
KG - Kirghizistan 9
NZ - Nuova Zelanda 8
RO - Romania 8
TH - Thailandia 8
BO - Bolivia 7
BZ - Belize 7
DZ - Algeria 7
NG - Nigeria 7
DK - Danimarca 6
GH - Ghana 6
GR - Grecia 6
JM - Giamaica 6
LB - Libano 6
NP - Nepal 6
TZ - Tanzania 6
BH - Bahrain 5
ET - Etiopia 5
KZ - Kazakistan 5
AL - Albania 4
BY - Bielorussia 4
CY - Cipro 4
EU - Europa 4
KH - Cambogia 4
MD - Moldavia 4
OM - Oman 4
RS - Serbia 4
EE - Estonia 3
GP - Guadalupe 3
HR - Croazia 3
LV - Lettonia 3
PR - Porto Rico 3
QA - Qatar 3
SN - Senegal 3
SV - El Salvador 3
UG - Uganda 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
Totale 25.442
Salva come PNG Salva come JPEG
Città #
Southend 1.620
Ashburn 1.398
Fairfield 1.270
Santa Clara 1.201
Singapore 1.008
Woodbridge 829
Hong Kong 645
Chandler 644
Houston 623
Ann Arbor 487
San Jose 483
Seattle 470
Wilmington 455
Cambridge 450
Jacksonville 418
Beijing 358
Dearborn 320
Nyköping 307
Hefei 292
London 259
Helsinki 242
Council Bluffs 227
Chicago 224
Los Angeles 223
New York 213
Ho Chi Minh City 197
Modena 182
The Dalles 147
Frankfurt am Main 144
Hanoi 139
San Diego 132
Seoul 113
Princeton 100
Milan 96
Salt Lake City 89
Buffalo 85
Sofia 84
Izmir 81
Eugene 79
Moscow 76
Shanghai 76
Munich 73
Rome 71
Lauterbourg 67
Jakarta 63
São Paulo 60
Dallas 50
Dublin 48
Bremen 46
Casablanca 45
Elk Grove Village 42
Redwood City 42
Columbus 39
Phoenix 39
Falls Church 38
Des Moines 37
Fremont 33
Tokyo 33
Orem 32
Tampa 31
Warsaw 29
Atlanta 28
Da Nang 28
Guangzhou 28
Montreal 28
San Francisco 28
San Giuliano Milanese 28
Chennai 26
Boardman 25
Toronto 25
Bologna 24
Turku 24
Brussels 23
Miami 22
Baghdad 21
Norwalk 21
Brooklyn 19
Denver 19
Lancaster 19
Amsterdam 18
Belo Horizonte 18
Dong Ket 18
Haiphong 18
North Bergen 18
Rio de Janeiro 18
Sterling 18
Johannesburg 17
Nanjing 17
Charlotte 16
Dhaka 16
Ottawa 16
Poplar 16
Boston 15
Buenos Aires 15
Manchester 15
Nuremberg 15
Paris 15
Parma 15
Philadelphia 15
Quito 15
Totale 18.184
Salva come PNG Salva come JPEG
Nome #
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 630
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 625
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 530
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. 526
Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma 492
The undergraduate nursing student evaluation of clinical learning environment: an Italian survey [La valutazione dell'ambiente di apprendimento clinico da parte degli studenti del Corso di Laurea in Infermieristica: una indagine italiana] 465
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 458
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas 443
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: Evaluation based on data from 1450 patients 426
Acquired haemophilia in HIV negative, HHV-8 positive multicentric Castleman's disease: a case report 416
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 411
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 393
Cell-penetrating CaCO3nanocrystals for improved transport of NVP-BEZ235 across membrane barrier in T-cell lymphoma 392
Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) 385
Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine 374
Activity of BKM120 and BEZ235 against lymphoma cells 373
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy 364
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 363
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines 350
Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. 348
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 346
A concise review of lenalidomide therapy for follicular lymphoma 341
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells 341
Calcium-Carbonate Nanocapsules Improve the Efficacy of BEZ235 in Lymphoma a Cell Line: A Promising New Technology of Drug Delivery 337
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 335
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 322
Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma - response to Murphy et al 317
A model for predicting the risk of developing mild anemia (MA) in patients with lymphoid malignancy. A study of the Gruppo Italiano Studio Linfomi (GISL) 317
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 314
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 312
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines 311
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 307
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) Infection 305
Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw. 303
Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma 299
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy 295
Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases 292
BISPHOSPHONATES (BP) RELATED OSTEONECROSIS OF THE JAW (ONJ): A LONG TERM FOLLOW UP (FU) OF A SERIES OF 35 CASES OBSERVED BY GISL 289
A RANDOMIZED PHASE II STUDY (GISL - MM03 TRIAL) WITH ORAL MELPHALAN+ PREDNISONE (MP) VERSUS MELPHALAN, + PREDNISONE + THALIDOMIDE (MPT) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA 284
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) InfectionBlood (ASH Annual Meeting Abstracts), Nov 2008; 112: 3054 281
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 280
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients 280
The potential of pralatrexate as a treatment of peripheral T-cell lymphoma 278
Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts 278
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. 274
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era 269
Diffuse Large B-Cell Lymphomas (DLBCL) with Hepatitis-C Virus (HCV) Infection: Incidence, Clinical Outcome and Preliminary Results of Antiviral Treatments (AVT) after Chemotherapy. 265
A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. 262
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease 255
A high-affinity fully human anti-IL-6 mAb (OP-R003-1, 1339) for the treatment of Multiple Myeloma 253
Secondary malignancies after treatment of aggressive non-Hodgkin lymphoma: A GISL cohort study on 1259 patients 252
Bortezomib and plasma cell leukemia 252
Low-molecular-weight heparin for vertebral artery dissection 249
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 247
Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts).Final Results of FC + R Phase II Trial by the GISL. 238
The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo 237
Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination 236
Bisphosphonates-associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time 230
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 228
The therapeutic strategy of HDAC6 inhibitors in lymphoproliferative disease 227
Introduction of Combined Chemotherapies Plus Rituximab (R) Has Improved Outcome of Previously Untreated and Relapsed Follicular Lymphoma (FL) Patients (pts).. 224
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts 222
In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma 221
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. 221
Diffuse B-large cell lymphomas with hepatitis C virus (HCV) infection: An interim report of a comparative study with or without antiviral treatment after chemotherapy 220
High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. 216
Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting 214
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. 213
The role of bisphosphonates in multiple myeloma: Mechanisms, side effects, and the future 210
AT7519, a Novel Small Molecule Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma VIA GSK3 beta 207
Antiviral treatment with interferon +/- ribavirin after chemotherapy for diffuse large B-cell non-Hodgkin lymphomas with hepatitis C virus (HCV) infection 202
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED FOLLICULAR LYMPHOMAS: LOW TOXICITY AND EXTENDED PROGRESSION FREE SURVIVAL. R1235 Barcelona, Spain. Bone Marrow Transplantation March 2004, Volume 33, Supplement 1 198
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice 197
Role of thalidomide in previously untreated patients with multiple myeloma 183
Targeting Bruton's Tyrosine Kinase As a Novel Approach to Inhibit Osteoclast Function in Multiple Myeloma 181
The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis 179
A simple and safe nomogram for the management of oral anticoagulation prior to minor surgery 178
Bisphosphonates and Atypical Femoral Fractures 176
From Osteoclast Differentiation to Osteonecrosis of the Jaw: Molecular and Clinical Insights 174
Clinicopathological, cytogenetic, and molecular profiles of primary cutaneous diffuse large B-cell lymphomas 171
Fatty acid synthase is a novel therapeutic target in multiple myeloma. 159
Nonpeghylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity 148
Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study 148
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study 140
Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: A case report and review of the literature 139
Clinical trials of bisphosphonates in multiple myeloma 129
Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: Pathophysiology, clinical presentation, and treatment 123
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3Β activation and RNA polymerase II inhibition 119
Management of adverse events and supportive therapy in relapsed/refractory multiple myeloma 117
Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study) 110
Autologous stem cell transplantation for newly diagnosed follicular lymphomas: low toxicity and extended progression free survival 99
Primary cardiac lymphoma: A case report and review 82
A new digital droplet PCR method for looking at epigenetics in diffuse large B‐cell lymphomas: The role of BMI1, EZH2, and USP22 genes 36
Totale 25.658
Salva come PNG Salva come JPEG
Categoria #
all - tutte 94.997
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 94.997
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.681 0 166 203 63 40 153 100 95 193 148 314 206
2022/20231.821 197 221 163 192 189 263 44 157 250 14 79 52
2023/20241.410 74 77 70 155 322 98 200 160 23 32 70 129
2024/20253.793 123 50 88 270 819 610 288 195 398 171 332 449
2025/20268.046 431 297 563 962 1.221 617 919 447 800 725 591 473
2026/2027315 259 56 0 0 0 0 0 0 0 0 0 0
Totale 25.658